Rene Kuijten

Partner, head of EQT Life Sciences (formerly LSP), member EQT Private Capital management team

2001 - Current

With a team of experienced and dedicated investment professionals, EQT Life Sciences (formerly LSP) supports top researchers since 1998 to develop new drugs and technologies for both major diseases as well as rare indications. EQT Life Sciences is Europe's largest life sciences investor with €3.5 billion assets under management in 12 funds and offices in Amsterdam, Munich and Boston. We have founded and successfully developed more than 300 companies and brought over 100 products to market that improved millions of patients' lives. Closed LSP 7 in February 2022, the first life sciences venture fund in Europe reaching €1 billion. Closed the EQT Dementia Fund in March 2023 at €270 million. As Head of EQT Life Sciences responsible for the overall strategy, management and fundraising for the Life Sciences, as well as for specific investments. Supervisory board director of twelve companies that were successfully exited, a.o. Kudos (sold to AstraZeneca, and developing Olaparib, a multibillion dollar new cancer drug), Neuravi (sold to J&J, stroke therapy) and Simplify Medical (sold to Nuvasive, cervical disc replacement).

Managing partner (LSP was acquired by EQT and renamed to EQT Life Sciences)

2001

LSP was acquired by EQT on February 28, 2022. With LSP we have built the European leader in life sciences investments, culminating in February 2022 in the largest life sciences venture fund to reach the €1 billion mark: LSP 7. Subsequently, LSP joined EQT Group to form EQT Life Sciences. EQT, originating from Sweden's Wallenberg family, is one of the largest European, and a top-ten global private equity player with over €100 billion assets under management. With EQT, we can raise even larger funds and do more and better investments, benefitting from EQT's large fundraising capabilities and its strong healthcare platform.

Initiator & founder, vice-chairman Supervisory Board

2012

The excellent Dutch cancer research needs to be translated into new treatments to help patients. With this goal we founded Oncode Institute, bringing together in 1 institute the best 1000 cancer researchers as well as business builders and drug developers, funded with EUR 75 mln per year from the participating 9 research institutes, the Dutch Cancer Foundation (KWF) and the government. Our Queen Maxima opened Oncode Institute in february 2018. Chairman in 2023.

Initiator and member Supervisory Board

2022

Oncode Accelerator is a Dutch public-private institute with €325 mln funding from the National Growth Fund. It aims to innovate and accelerate the development of new cancer therapies by improving preclinical development. It works closely with Oncode Institute (who initiated Oncode Accelerator) and with 30 partner institutes.

Fellow

2023

The Academy focuses on applying technological innovations to address societal challenges

Advisory Board Topsector Life Sciences and Health

2011

Initiator of a.o. the Oncode Institute and Oncode Accelerator

Jury member Agnites Vrolik Prize

2018

International Advisory Board Utrecht Life Sciences (ULS)

2017 - 2023

Royal Dutch Society for Sciences and Humanities

2016

Oldest society for sciences in The Netherlands (since 1752)

Member

2009 - 2023

Raad van Advies

2020 - 2022

Advisory council for prevention in care at health insurer Menzis